IP Library Granted Patent US 8,168,391
Granted Patent B2
US 8,168,391 · App. 12/267,507 · Granted May 1, 2012

Method for modulating insulin production

Assignees: Burnham Institute for Medical Research; The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,168,391
App. No.
12/267,507
Granted
May 1, 2012
Kind
B2
Abstract

The present invention provides screening methods for the detection of agents that affect various aspects of β-cell biology, particularly insulin gene expression. Screening methods are also provided for detection of agents that affect β-cell differentiation from progenitor cells. Additionally, agents identified using such methods are provided and are useful for increasing insulin gene expression and reducing lipotoxicity.

Claims (17)

1. A method of screening for an agent that reduces lipotoxicity in a subject having Type I or Type II diabetes comprising:

a) transfecting a cell with a vector comprising an insulin promoter operably linked to a nucleic acid encoding a reporter protein, wherein the reporter protein is a fluorescent protein;

b) contacting the cell with a candidate agent; and

c) detecting the reporter protein, thereby identifying an agent that reduces lipotoxicity.

2. The method of claim 1 , where the cell is derived from a human fetal islet cell.

3. The method of claim 1 , wherein the cell is further contacted with a fatty acid.

4. The method of claim 3 , wherein the fatty acid is palmitate.

5. The method of claim 1 , wherein the subject is a human.

6. The method of claim 1 , wherein the cell is transfected in solution and then cultured in a microtiter plate.

7. The method of claim 6 , wherein the cells are culture 4 days before detection.

8. The method of claim 1 , wherein the fluorescent protein is green fluorescent protein (GFP) or enhanced green fluorescent protein (eGFP).

9. The method of claim 1 , wherein detection of the reporter protein is performed using fluorescence microscopy.

10. The method of claim 1 , wherein the screening is performed in a high throughput format.

11. A method of screening for an agent that reduce lipotoxicity in a subject having Type I or Type II diabetes comprising:

a) transfecting a cell with a vector comprising an insulin promoter operably linked to a nucleic acid encoding a reporter protein, wherein the reporter protein is green fluorescent protein (GFP) or enhanced green fluorescent protein (eGFP);

b) contacting the cell with a candidate agent; and

c) detecting the reporter protein, thereby identifying an agent that reduces lipotoxicity.

Assignments (4)
CONFIRMATORY LICENSE Recorded Aug 22, 2012
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028828/0076 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2009
From: MERCOLA, MARK
To: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
Reel/Frame 022825/0075 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2009
From: LEVINE, FRED; ITKIN-ANSARA, PAMELA
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 022825/0085 →
CONFIRMATORY LICENSE Recorded Mar 17, 2009
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 022406/0459 →
Continuity (2)
Provisional Application 60986239 · Nov 7, 2007
Related Publication 20090137543A1 · May 28, 2009